Results 61 to 70 of about 1,262,540 (308)

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

BMC Cancer
Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies.
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria   +13 more
doaj   +1 more source

Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]

, 2015
BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T, Janku, Filip, Kurzrock, Razelle, Moulder, Stacy L, Stephens, Philip J, Wheler, Jennifer J, Yelensky, Roman   +6 more
core   +2 more sources

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. [PDF]

, 2017
BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size ...
A Sundin, AA van der Veldt, Angela Lamarca, BE Houk, Catherine Lombard-Bohas, E Raymond, EA Eisenhauer, Eric Raymond, Heinz-Josef Lenz, HX Chen, HZ Shi, Ivan Borbath, James Posey, JC Yao, Jean Luc Raoul, Jorge Barriuso, Juan W Valle, KM Krajewski, KM Krajewski, Matthew Kulke, MC Ornstein, MH Kulke, Neal J Meropol, P Therasse, R Thiam, S Faivre, S Patel, Sandrine Faivre   +27 more
core   +2 more sources

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Cancer Management and Research, 2014
Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon,
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C   +5 more
doaj  

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

The Application of Clinical Genetics, 2022
Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS, Soliman SE, Elhamouly MS, Gohar SF, Elgamal A, Alabassy MM, Soliman HA, Gadallah AA, Elbahr OD, Soliman G, Saleh AA   +10 more
doaj  

Long Term Clinical Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Single Center Study [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Objectives Few studies have reported long-term follow-up after treatment of gastric mucosaassociated lymphoid tissue (MALT) lymphoma. In this single-center study, we investigated longterm treatment outcomes in patients diagnosed with gastric MALT ...
Seong Hyun Koh, Seung Hyun Yeo, Moo In Park, Kyoungwon Jung, Sung Eun Kim, Won Moon, Seun Ja Park   +6 more
doaj   +1 more source

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer

Frontiers in Nutrition, 2023
BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie, Hailun Xie, Lishuang Wei, Shunhui Gao, Shunhui Gao, Mingxiang Liu, Mingxiang Liu, Yanren Liang, Yanren Liang, Guanghui Yuan, Guanghui Yuan, Qiwen Wang, Qiwen Wang, Yansong Xu, Shuangyi Tang, Jialiang Gan, Jialiang Gan   +16 more
doaj   +1 more source

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial [PDF]

, 2016
Despite an improved antitumor efficacy as noticed by an enhanced response rate and an improved progression-free survival, the hepatic intra-arterial fotemustine did not increase the overall survival of uveal melanoma patients with liver metastases only ...
Baurain, J. F., Durando, X., Gurunath, R. Karra, Jouary, T., Kaempgen, E., Keilholz, U., Leyvraz, S., Marshall, E., Negrier, S., Piperno-Neumann, S., Schadendorf, D., Scheulen, M., Suciu, S., Testori, A., Vermorken, J. B., Zdzienicki, M.   +15 more
core   +2 more sources